Lawmakers impatient with the lack of progress on a key health care issue — the long-debated need for changes to what’s known as the 340B drug pricing program — say they are closing in on legislation ...

As the Trump administration begins to make its mark on the Medicare drug price negotiation program, litigation over the program continues. In the two years since the first case challenging the program ...

WASHINGTON — The Food and Drug Administration commissioner’s effort to drastically shorten the review of drugs favored by President Trump’s administration is causing alarm across the agency, stoking ...

ALBANY — Some lawmakers in New York are calling for increased transparency and oversight over a controversial federal drug discount program that benefits many of the state’s larger hospitals, as a ...

Expedited development and review programs established by the US Food and Drug Administration (FDA) have a growing role in bringing drugs and biologics to market, with novel orphan and nonorphan ...